Background: The aim of the study was to evaluate the feasibility and efficacy of a non-myeloablative regimen to achieve complete donor chimerism after stem cell transplantation (SCT) in patients with metastatic solid tumors. Patients and methods: Seven patients with renal cell carcinoma (RCC), 3 with colorectal carcinoma and 1 with soft tissue sarcoma received an allogeneic SCT after fludarabine (90 mg/m2) and TBI 200 cGy. Results: At day 30, median donor chimerism was 94%. Regression of tumor metastases has been observed in 1 patient with RCC. Overall, 8 patients (73%) died from progressive disease (median progression-free survival 3.7 months) and 1 (9%) from treatment-related complications; 2 patients were alive 152 and 862 days after transplantation. Conclusions: Our preliminary results suggest that non-myeloablative SCT for metastatic solid tumors is feasible, although may lead to durable responses in a minority of patients. Careful patient selection seems to be mandatory in this transplant setting.

Busca, A., Novarino, A., DE FABRITIIS, P., Picardi, A., Zeuli, M., Locatelli, F., et al. (2006). Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors. HEMATOLOGY, 11(3), 171-177 [10.1080/10245330600775253].

Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors

DE FABRITIIS, PAOLO;PICARDI, ALESSANDRA;
2006-01-01

Abstract

Background: The aim of the study was to evaluate the feasibility and efficacy of a non-myeloablative regimen to achieve complete donor chimerism after stem cell transplantation (SCT) in patients with metastatic solid tumors. Patients and methods: Seven patients with renal cell carcinoma (RCC), 3 with colorectal carcinoma and 1 with soft tissue sarcoma received an allogeneic SCT after fludarabine (90 mg/m2) and TBI 200 cGy. Results: At day 30, median donor chimerism was 94%. Regression of tumor metastases has been observed in 1 patient with RCC. Overall, 8 patients (73%) died from progressive disease (median progression-free survival 3.7 months) and 1 (9%) from treatment-related complications; 2 patients were alive 152 and 862 days after transplantation. Conclusions: Our preliminary results suggest that non-myeloablative SCT for metastatic solid tumors is feasible, although may lead to durable responses in a minority of patients. Careful patient selection seems to be mandatory in this transplant setting.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - Malattie del Sangue
Settore MED/05 - Patologia Clinica
English
Con Impact Factor ISI
nonmyeloablative regimen; allogeneic stem cell transplantation; graft versus tumor effect; solid tumors
Busca, A., Novarino, A., DE FABRITIIS, P., Picardi, A., Zeuli, M., Locatelli, F., et al. (2006). Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors. HEMATOLOGY, 11(3), 171-177 [10.1080/10245330600775253].
Busca, A; Novarino, A; DE FABRITIIS, P; Picardi, A; Zeuli, M; Locatelli, F; Bertetto, O; Falda, M
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
37.pdf

non disponibili

Licenza: Copyright dell'editore
Dimensione 82.35 kB
Formato Adobe PDF
82.35 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/36830
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 2
social impact